Toggle navigation
Home
Feed
Channels
Profile
Home
Feed
Channels
Profile
Medspoke's Talks
Medspoke
Medspoke
BJU International
Published September 13, 2026
Intermittent enzalutamide in recurrent prostate cancer: testosterone kinetics and related toxicity.
September 14, 2026
Medspoke
Medspoke
BJU International
Published September 13, 2026
00:00
--:--
Prospective randomised double-blind trial: holmium laser lithotripsy with vs without Moses™ 2.0.
September 14, 2026
Share
Prospective randomised double-blind trial: holmium laser lithotripsy with vs without Moses™ 2.0.
https://www.medspoke.co/channel_journal?id=689&tap_id=13885
Copy Link
Email
X
Bluesky
WhatsApp
LinkedIn
Facebook
Reddit
Medspoke
Medspoke
World Allergy Organization Journal
Published September 2, 2026
Clinical and genetic characterization of X-linked agammaglobulinemia in a Colombian cohort.
September 14, 2026
Why are you reporting this TALK?
